AI holds untapped potential in heart failure developments, but thoughtful evaluation matters.
JCF’s upcoming Focus Issue will explore where innovation meets evidence, submit your research by June 15th, 2026.
https://bit.ly/4kJl5gf
#HeartFailure #AIinHealthcare #CallForPapers
What’s new in heart failure research this month? 💡
The April issue of JCF has the latest studies and perspectives.
Start reading 👉 https://onlinejcf.com/current
How quickly do GLP-1 therapies benefit patients with HF? 🫀
A new research letter found semaglutide reduced HF hospitalization and mortality within ~150 days. Benefits were similar in HFmrEF and HFpEF, and sustained with continued GLP-1 therapy. 📊
🔗 https://bit.ly/40WyEjf
Can patients hospitalized with worsening HF be treated at home?🏠
A new brief report suggests many patients who meet traditional Hospital-at-Home criteria may be good candidates, highlighting the potential for HaH to reshape care delivery for worsening HF. ❤️🩹
🔗 https://bit.ly/4sC21nf
How quickly do kidneys adapt to salt intake?🧂
In healthy volunteers, urinary sodium tracked dietary changes within ~3 days.
But intake and excretion weren’t perfectly matched, suggesting a dynamic sodium reserve maintained by the kidneys. 💧
🔗 https://bit.ly/4s0j15B
Final Call 🚨
Submissions close tomorrow for JCF’s Focus Issue on Innovations in Heart Transplantation.
If your research offers new insight into transplantation techniques, outcomes, or care models, don’t miss the deadline 👉 April 10, 2026
#CallForPapers #HeartTransplantation #Cardiology
NT-proBNP measured 2 weeks after high-risk MI ❤️🩹predicts outcomes.
In a PARADISE-MI analysis, higher levels were independently linked to risk of HF, CV death, recurrent MI & all-cause death, highlighting the early convalescent phase for risk stratification.
🔗 https://bit.ly/4lJ2y3U
One week remains to submit to JCF’s Focus Issue on Innovations in Heart Transplantation. ⌛
We’re seeking research that advances transplantation strategies, outcomes, and clinical decision-making.
🗓️ Deadline: April 10, 2026
#CallForPapers #HeartTransplantation #Cardiology
The accompanying editorial calls for action🚨
Identify GDMT gaps early, initiate Rx in supportive settings, & build systems that allow safe, rapid optimization of HF Rx.
The issue isn’t whether GDMT works, it’s whether systems will invest in delivering it.
🔗 bit.ly/4rTor1T
New science🚨! Early initiation & uptitration of Sac/Val💊 vs ACEI/ARB in pts w/AHF led to ⬆️NT-proBNP reduction w/o AEs.
Sac/Val💊 uptitration linked to:
⬇️kidney dysfunction
⬆️NYHA class.
Results support timely Sac/Val initiation & thoughtful uptitration🚀.
🔗 bit.ly/4sDtAfR
In ambulatory HFpEF, 🫁ultrasound detected pulm congestion more often than routine exam.
Higher B-line burden linked to worse symptoms, ⬆️ NPs & filling pressures; yet ~40% in highest tertile had no crackles or ⬆️ NT-proBNP.
LUS may aid congestion monitoring.
🔗 https://bit.ly/4rNOJTe
📣 Two weeks remain to submit to JCF’s Focus Issue on Innovations in Heart Transplantation.
Now is the time to share research shaping what comes next.
🗓️ Deadline: April 10, 2026
#CallForPapers #HeartTransplantation #Cardiology
📊Method/Design Article - ENVAD-HF: first prospective RCT of HF meds in stable HeartMate 3 LVAD pts.
Comparing sacubitril/valsartan vs SOC for BP (MAP 75–90). Primary safety endpoint: death, renal decline, hyperK, hypotension. Results soon!
🔗 https://bit.ly/4rVT7QD
📍 Filmed at #THT2026
🤝 In collaboration with @crfheart.bsky.social and @hfsa.bsky.social
#AIinMedicine #ClinicalTrials #HeartFailure
🎥 #THT2026 Hot Take
AI is starting to reshape clinical trials.
With Jon Cunningham, we discussed:
Can AI based digital twins will replace the gold standard of randomizing patients in clinical trials?
and how AI can aid in the efficient adjudication of clinical events 🤔
Watch the discussion!
❤️ LVAD-first or transplant-first in younger advanced HF pts?
A new JCF Ignite! perspective suggests an LVAD-first strategy may offer survival comparable to transplant, preserve future transplant options, and even enable myocardial recovery.
🔗 https://bit.ly/4rnADbL
🫀 Fontan pts are now the largest CHD subgroup listed for pediatric HT.
Waitlist survival has improved📈
But post-HT graft loss remains ~2x higher vs cardiomyopathy⚠️
⬆️infection & malignancy🦠
VAD bridging shows better outcomes than ECMO in Fontan pt. ❤️🩹
🔗 https://bit.ly/4aGzANc
Check out the editorial:
1️⃣Lp(a) check identifies pts at ⬆️ risk of CV death or HF hosp🏥 (even accounting for NT-proBNP 🧪)
2️⃣Lp(a)+NT-proBNP ⚖️ = better risk stratification
3️⃣Lp(a)>50 mg/dL 💊📈 = consider aggressive lipid-lowering & closer follow-up
🔗 bit.ly/46ZIofV
🧬Lp(a) predicts new-onset HF, but does it matter in chronic HF? 🤔
In >1K HF pts, Lp(a) ≥30 mg/dL was linked to a 35% ⬆️ risk of CV death or HF hosp🏥, independent of NT-proBNP. The signal was stronger in ischemic HF.
⚠️High Lp(a)+NT-proBNP = highest-risk
bit.ly/4cBlbEv
Heart transplantation is entering a new era — shaped by innovation, data, and clinical insight.
JCF invites submissions for a dedicated Focus Issue on Innovations in Heart Transplantation.
📅 Deadline: April 10, 2026.
#CallForPapers #HeartTransplantation #Cardiology
❤️🩹HCM in pregnancy is rising fast: prevalence increased ~400% from 2000–2021, with the largest increase among Black adults.
Black pts with HCM also had ⬆️adverse pregnancy outcomes.
Highlights growing need for equitable cardio-obstetric care.
🔗 https://bit.ly/46haFyh
🧂Should all HF pts restrict sodium? A post-hoc Bayesian HTE analysis of SODIUM-HF suggests effects vary by MAGGIC risk:
✅ Lower-risk pts may benefit (incl KCCQ)
⚠️ Highest-risk pts may be harmed.
Not one-size-fits-all.
🔗 https://bit.ly/3OlFc84
From predictive analytics to clinical decision support, AI is rapidly influencing heart failure management.
Submit your research to JCF’s upcoming Focus Issue:
Artificial Intelligence and Heart Failure: A Critical Juncture
🗓️ Due May 10, 2026
https://bit.ly/4kJl5gf
#HeartFailure #AIinHealthcare
Call for Papers 🚨
Focus Issue: Innovations in Heart Transplantation
JCF’s upcoming focus issue will examine the breakthroughs reshaping heart transplantation today.
Submit your research by April 10, 2026.
#CallForPapers #HeartTransplantation #Cardiology
🫀⚡CRT has transformed HF care, but nonresponse is common.
Key challenges:
• Pt selection & conduction disease characterization🎯
• Device programming⚙️
• Delayed referral⏱️ & equity gaps🤝
Conduction-system pacing may be the future
🔗 https://bit.ly/3MqLfaD
🫀#THTSimPub Alert
This 🔥State-of-the-Art Review examines HeartLogic, a multisensor algorithm embedded in existing CIEDs to detect early HF decompensation, as well as the DANLOGIC-HF RCT which will test whether guided management reduces HF events!
🔗 https://bit.ly/46D91Hv
🫀#THT2026 Sim Pub Alert🚨: A medically-trained LLM #AI model integrated within a health system EMR accurately screened pts for a rare ATTR-CM trial, providing eligibility justifications & improving diversity vs routine workflows.
🔗 https://bit.ly/4u8aAar
🫀🚨 #THTSimPub Alert!
✅ In >25K HF pts, higher GDMT scores were linked to ⬇️ mortality & hospitalization across EF, including HFmrEF & HFpEF.
✅ ARNI showed benefit vs ACEi/ARB across EF groups.
✅ Time to rethink GDMT in non-HFrEF populations?
🔗 https://bit.ly/3PftpII
#THTSimPub
As DCD 🫀 transplant grows, ethical, regulatory & oversight questions are intensifying.
A Perspectives piece from @MaryjaneFarrMD examines policy shifts, AST/ASTS guidance, & whether a pause on DCD is warranted as the transplant system evolves.
🔗 https://bit.ly/4lcknIz
🫀#THTSimPub
In INOCA pts undergoing IMR + exercise hemodynamics, higher IMR (chronic microvasc dysfx) was linked to early HFpEF physiology:
⬆️exercise RAP & PCWP
⬆️ PCWL
⬆️ prevalent ΔmPAP/ΔCO slope >3.
CMD may be an upstream driver of HFpEF.
🔗 https://bit.ly/4cmsH6d
